John S. Kovach - 06 Nov 2022 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
President and CEO, Director
Signature
/s/ John Kovach
Issuer symbol
LIXT
Transactions as of
06 Nov 2022
Net transactions value
$0
Form type
4
Filing time
09 Nov 2022, 15:55:19 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Stock Options Award $0 +200,000 $0.000000 200,000 06 Nov 2022 Common 200,000 $2.00 Direct F1
holding LIXT Warrants to Purchase Common Stock 21,100 06 Nov 2022 Common 21,100 $5.70 By John S. Kovach Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 6, 2022, the reporting person was granted options to purchase 200,000 shares of the issuer's common stock, exercisable for a period of 5 years at $2.00 per share, vesting 25% on the issuance date, and 25% on each anniversary date thereafter until fully vested, subject to continued service.